


Accepted Manuscript

Comparative study of anti-VEGF Ranibizumab and interleukin-6 receptor antagonist tocilizumab in adjuvant-induced arthritis

Amany El-Shahawy Abdel-Maged, Amany M. Gad, Amal Kamal Abdel-Aziz, Mohammad M. Aboulwafa, Samar S. Azab



PII: S0041-008X(18)30327-2
DOI: doi:[10.1016/j.taap.2018.07.014](https://doi.org/10.1016/j.taap.2018.07.014)
Reference: YTAAP 14338
To appear in: *Toxicology and Applied Pharmacology*
Received date: 14 April 2018
Revised date: 30 June 2018
Accepted date: 13 July 2018

Please cite this article as: Amany El-Shahawy Abdel-Maged, Amany M. Gad, Amal Kamal Abdel-Aziz, Mohammad M. Aboulwafa, Samar S. Azab , Comparative study of anti-VEGF Ranibizumab and interleukin-6 receptor antagonist tocilizumab in adjuvant-induced arthritis. Ytaap (2018), doi:[10.1016/j.taap.2018.07.014](https://doi.org/10.1016/j.taap.2018.07.014)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Comparative Study of anti-VEGF Ranibizumab and interleukin-6 receptor antagonist Tocilizumab in
Adjuvant-Induced Arthritis**

Amany El-Shahawy Abdel-Maged¹, Amany M. Gad², Amal Kamal Abdel-Aziz³, Mohammad M.

Aboulwafa⁴, Samar S. Azab^{3,*} samar_saad_azab@pharma.asu.edu.eg

¹National Organization for Research and Control of Biologicals (NORCB), Cairo, Egypt

²Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt

³Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

⁴Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

***Corresponding author at:** Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt

Abstract:

Although the precise etiology of Rheumatoid arthritis (RA) remains obscure, heightened immune response is thought to play a vital role in provoking joint inflammation and bone erosion. This study aims at comparatively evaluating the effects of two monoclonal antibodies Ranibizumab (RANI) as anti-VEGF antibody and Tocilizumab (TCZ) as interleukin-6 receptor (IL-6R) antagonist, against adjuvant induced arthritis in rats. CFA-induced arthritic rats were treated for three consecutive weeks with Methotrexate (MTX), TCZ and RANI monotherapy. Clinical assessment of RA, bone erosion, inflammatory, angiogenic and apoptotic markers were determined to assess the anti-arthritic effect. Liver enzymes and histopathological examination of liver and spleen were assessed to evaluate the toxicity profile of the tested therapeutic agents. MTX, TCZ and RANI monotherapy significantly

Download English Version:

<https://daneshyari.com/en/article/8537993>

Download Persian Version:

<https://daneshyari.com/article/8537993>

[Daneshyari.com](https://daneshyari.com)